X0508 4 2024-03-30 0001635088 Roivant Sciences Ltd. ROIV 0001750094 Gline Matthew C/O ROIVANT SCIENCES LTD. 7TH FLOOR, 50 BROADWAY LONDON X0 SW1H 0DB UNITED KINGDOM true true CEO true Common Shares 2024-03-30 4 M 0 390579 A 1380642 D Common Shares 2024-03-30 4 F 0 215991 10.54 D 1164651 D Capped Value Appreciation Rights 2024-03-30 4 M 0 994373 6.4 D 2026-03-31 Common Shares 390579 0 D Reflects the conversion of capped value appreciation rights ("CVARs") that entitle the reporting person, following the achievement of specified vesting and other conditions, to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the applicable hurdle price reflected in column 8 of Table II above (such excess, the "CVAR Amount"). On March 30, 2024, the "knock-in" condition (as defined below) and hurdle price applicable to the remaining 994,373 of these vested CVARs have been satisfied and, accordingly, the CVARs were settled into 390,579 Common Shares, determined by dividing (i) the CVAR Amount by (ii) the closing price of a Common Share on March 28, 2024. Represents the "net settlement" by the Issuer of CVARs in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the CVARs. This award of CVARs vested (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date, with a vesting commencement date of December 27, 2019. By: /s/ Jo Chen, as Attorney-in-Fact for Matthew Gline 2024-04-02